How to Evaluate PEMF Research: What Makes a Study Strong or Weak?

Summary: Published PEMF studies vary enormously in methodological quality, and publication alone tells you almost nothing about whether a study’s findings are reliable. A study can appear in a peer-reviewed journal, report a statistically significant result, and still be too small, too poorly controlled, or too incompletely reported to support the conclusions drawn from it. Knowing how to look past those surface signals is what separates a reader who can evaluate evidence from one who simply accepts it.

The good news is that evaluating PEMF research does not require a statistics degree. It requires knowing which specific features to examine: how participants were assigned to groups, whether a credible sham control was used, whether the sample was large enough to detect a real effect, whether the reported outcome was prespecified, whether the study’s PEMF parameters were fully disclosed, and whether the finding has been independently replicated. Each of these dimensions contributes to the overall strength or weakness of the evidence. No single feature tells the whole story, and no design label, however prestigious, substitutes for actually examining them.

Evaluating PEMF research requires more than checking whether a study reported a positive result. Study design, sample size, population, device type, frequency, intensity, waveform, exposure conditions, measured endpoints, and limitations all affect how much confidence a finding deserves. For the broader evidence framework, see our guide to PEMF research and evidence, which explains how individual studies fit into the wider research landscape and how cautiously their findings should be applied to consumer PEMF mats.

Not All PEMF Studies Are Created Equal: Understanding Study Design Types

The first question to ask when you encounter a PEMF study is: what kind of study is this? Different designs offer different levels of control over the factors that can distort a result, and understanding the hierarchy helps you calibrate how much weight to assign the findings before examining anything else.

A randomized controlled trial (RCT) assigns participants to active treatment or a control condition using a random method, such as computer-generated allocation. Because assignment is determined by chance rather than by the participant’s characteristics or a researcher’s judgment, groups should be roughly equivalent at the start of the study. This comparability is what makes it possible to attribute differences in outcomes to the treatment itself rather than to pre-existing differences between groups.

An observational study follows participants without controlling their exposure. Researchers watch what happens to people who receive or choose a treatment versus those who do not, but they do not intervene in that choice. Because people who seek out PEMF therapy may differ in important ways from those who do not, it is much harder to attribute observed differences to the treatment rather than to those underlying differences.

A systematic review uses a structured, predefined methodology to identify, assess, and synthesize all available research on a question. A meta-analysis goes further by statistically pooling results from multiple studies to produce a combined estimate. These designs sit at the top of most evidence hierarchies because they aggregate findings rather than relying on any single study. However, that advantage comes with an important constraint: a systematic review is only as strong as the studies it includes. Pooling a collection of small, poorly controlled trials does not produce a large, well-controlled one. The quality of the inputs determines the quality of the output.

The hierarchy exists because more structured designs offer greater control over confounding, but design type is a starting point for evaluation, not a verdict. A small, poorly executed RCT with missing parameters and an unblinded outcome assessor may be weaker evidence than a carefully conducted observational study with robust methods and complete reporting. What determines whether a design’s theoretical advantage is actually realized is execution quality and reporting transparency, which the following sections address in detail.

How Randomization and Allocation Concealment Reduce Selection Bias

Randomization reduces selection bias by assigning participants to groups through a chance process rather than according to participant characteristics or researcher judgment. In expectation, this helps prevent systematic baseline differences between groups, including differences in characteristics that researchers did not measure. Individual trials - especially small ones - can still show baseline imbalances by chance.

When randomization is properly implemented and other major sources of bias are controlled, differences in outcomes between groups can be interpreted more credibly as effects of the assigned intervention rather than pre-existing group differences.

A separate safeguard needed to preserve the benefit of randomization is allocation concealment:  the procedure that prevents researchers or recruiters from knowing a participant’s upcoming group assignment before that participant is enrolled. This matters because, without concealment, a researcher who knows the next assignment slot might consciously or unconsciously enroll a patient with a better prognosis when the next slot is for the active treatment group, or reserve a more severe case for the control. Neither action need be deliberate to introduce systematic distortion.

Methods that support allocation concealment include centralized randomization managed by an independent party, sequentially numbered sealed opaque envelopes, and pharmacy-controlled dispensing. A study that claims randomization but provides no information about how allocation was concealed has a weakened design advantage, because the bias that randomization was meant to prevent may have quietly re-entered through the enrollment process.

When reading a PEMF study, the practical check is straightforward: look for a description of the randomization method and a description of how allocation was protected. If neither appears, treat the study’s RCT label with appropriate caution. Design intent and design execution are not the same thing.

Sham Controls and Why Blinding Works Differently in PEMF Research

Understanding blinding requires understanding what it is protecting against. Even in a well-randomized trial, if participants know they are receiving active treatment, their expectations can improve self-reported outcomes independently of any physiological effect. If the researchers assessing outcomes know which group a participant is in, their judgments can be subtly influenced in the same direction. Blinding prevents this by keeping both participants and outcome assessors unaware of group assignment throughout the study.

In PEMF research, the mechanism for achieving this is the sham control device: a unit that is visually and audibly identical to the active PEMF device but delivers no active magnetic field. The device looks the same, makes the same sounds, and produces the same visual indicators during a session. A participant using it has no basis, purely from the experience of using it, to determine whether the field is active.

PEMF can offer a useful blinding advantage when the active exposure produces no perceptible heat, vibration, muscle contraction, sound, or other sensory cue. Under those conditions, an inactive sham device can potentially reproduce much of the participant experience while withholding the magnetic-field exposure.

Other physical interventions can also use sham controls, but their credibility depends on whether the sham successfully reproduces the sensory and procedural experience of the active intervention without delivering the treatment component being tested. The relevant question is therefore not whether PEMF is inherently blindable, but whether participants and outcome assessors in the particular study could reliably distinguish active from sham treatment.

The practical implication is that double-blinding is a reasonable and meaningful standard for evaluating PEMF trials, not an aspirational ideal that researchers should receive credit for merely attempting. When a sham-controlled PEMF study claims double-blinding, the natural follow-up questions are: Did the device produce any sensory output that could have revealed allocation? Did the study report a blinding verification check, such as asking participants at the end of the study which group they believed they were in?

One important qualifier: sham credibility must be evaluated per study. Higher-intensity PEMF protocols that produce perceptible muscle contraction are an exception; participants in those studies can detect treatment delivery, which compromises blinding in the same way physical therapy modalities are compromised. A stated claim of double-blinding does not automatically mean the blinding held. The study has to have actually maintained it, and a well-reported study will give you enough information to assess whether it did.

Execution Quality: How Risk of Bias Can Undermine a Well-Designed Study

Even a study with a sound design can produce unreliable results if the execution is flawed. Risk of bias refers to the possibility that systematic factors in how a study was designed, conducted, analyzed, or reported distort the estimated result. It is a methodological concept, not a synonym for misconduct or fraud. Most bias in clinical research arises from structural features of how studies are run, not from any intent to mislead.

Risk of bias is multidimensional. Modern frameworks evaluate several distinct ways in which the estimated result of a randomized trial can be distorted. The Cochrane Risk of Bias 2 framework organizes these into five domains:

● Bias arising from the randomization process: whether the allocation sequence was genuinely random, adequately concealed, and free from important problems that could create systematic baseline differences.

● Bias due to deviations from intended interventions: whether knowledge of group assignment or departures from the assigned intervention affected the result being estimated.

● Bias due to missing outcome data: whether unavailable outcome data could plausibly distort the estimated effect.

● Bias in measurement of the outcome: whether the outcome was measured appropriately and whether knowledge of the intervention could influence the measurement or assessment.

● Bias in selection of the reported result: whether the reported outcome, time point, or analysis may have been selected from multiple eligible possibilities based on the results.

These domains are evaluated separately because a trial can perform well in one and poorly in another. Strong randomization does not compensate for substantial missing outcome data, and credible participant blinding does not prevent selective reporting. Study design provides the structure for reducing bias; execution, analysis, and reporting determine how well that protection holds for the particular result being interpreted.

Why Sample Size Affects What a Study Can Actually Detect

Statistical power is the probability that a study will detect a real effect if one exists. A study with adequate statistical power has a higher probability of detecting an effect of the size it was designed to detect, if that effect truly exists and the study assumptions are approximately correct.

Two types of statistical errors are commonly discussed in hypothesis testing. A Type I error occurs when the null hypothesis is rejected even though it is true under the statistical model being tested. A Type II error occurs when the study fails to reject the null hypothesis even though an effect of the relevant size exists. Small sample size can increase the risk of a Type II error by reducing statistical power, but it is not the only factor involved. For readers of PEMF research, the practical lesson is that a nonsignificant result—especially in a small or imprecise study—should not automatically be interpreted as proof that no effect exists.

Consider an illustrative scenario: a PEMF pilot study enrolls 14 participants with chronic joint discomfort. The active treatment group shows a clinically meaningful improvement in their symptom scores. However, with only 7 participants per group, the estimates are highly variable, and the difference does not reach statistical significance (p is greater than 0.05). This is not evidence that PEMF has no effect. The study may simply be too small to distinguish the observed difference reliably from sampling variation. The appropriate interpretation is uncertainty, not proof of either benefit or no benefit.

The inverse problem also matters, and it feeds directly into the next section. A very large study can find a statistically significant difference that is mathematically real but too small for any patient to notice. With a sample of several thousand participants, even a trivially small average difference between groups may cross the significance threshold. Statistical significance in that context indicates that the observed data are relatively incompatible with the specified null model; it does not tell you whether the difference is large or clinically important. It says nothing about whether the difference is worth caring about.

Both of these problems mean that sample size must always be evaluated alongside the size of the reported effect. A large, precisely estimated difference in a study of 300 participants means something quite different from a barely significant difference in a study of 3,000.

Conflicts of Interest, Funding Source, and Attrition: What Else Can Bias a Study’s Results

Funding source is relevant when evaluating clinical research. Empirical reviews of drug and medical-device studies have found that industry-sponsored studies are more likely than non-industry-sponsored studies to report efficacy results and overall conclusions favorable to the sponsor's product. That association does not mean an industry-funded study is invalid, and it is not fully explained by the standard risk-of-bias domains. Potential contributors can include differences in study questions, populations, comparators, outcomes, analysis choices, or interpretation, which is why funding and conflicts of interest should be considered alongside the study's methods rather than used as an automatic reason for dismissal.

The appropriate response to identified industry funding is closer scrutiny, not automatic dismissal. An industry-funded study with a strong design, transparent reporting, prespecified primary endpoints, and independent outcome assessment can still be informative. The question is whether the study’s methods are strong enough to constrain the channels through which funding influence typically operates.

Attrition bias arises from a different mechanism. When participants drop out of a study before it concludes, the remaining sample may no longer represent the population that started the trial. The bias occurs specifically when dropout is related to the outcome: if participants who experienced worsening symptoms were more likely to stop attending sessions and withdraw from the study, the remaining participants disproportionately represent those who tolerated or benefited from treatment. Their outcomes, reported at the end, look more positive than they would have if all original participants had been retained and measured.

A study with substantial dropout should clearly report how many participants were lost from each group, when they left, why outcome data are missing when known, and how the analysis handled those missing data. In randomized trials, keeping participants in the groups to which they were originally assigned helps preserve the benefit of randomization. However, describing an analysis as “intention-to-treat” does not by itself solve missing-data problems: if outcome measurements are unavailable, the assumptions and statistical methods used to handle those missing values still matter. A report that analyzes only participants who completed the full protocol, without explaining exclusions or missing outcomes, deserves additional scrutiny.

What a Positive Result Actually Tells You: Statistical Significance vs Clinical Significance

A positive result in a PEMF study is not a single thing. It can mean a finding that is mathematically unlikely to be due to chance. It can mean an effect that is large enough to matter to a patient. Or it can mean both. These three concepts, statistical significance, effect size, and clinical significance, are distinct, and conflating them is one of the most common and consequential errors in reading clinical research.

The distinction is not subtle, and it has direct practical implications. A study can achieve statistical significance with an effect so small that patients would never notice it. A study can show a clinically meaningful effect that fails to reach significance because the sample was too small. And a very large effect can be both statistically and clinically significant. Understanding which situation you are in when reading a PEMF abstract requires looking at more than the p-value.

The Difference Between a Statistically Significant and a Meaningfully Large Effect

Statistical significance is often summarized using a p-value. A p-value describes how incompatible the observed data are with a specified statistical model, usually one in which there is no true difference between groups. For example, a p-value below 0.05 means that, if the null model and its assumptions were correct, results at least as incompatible with that model as those observed would occur less than 5% of the time.

It does not mean there is less than a 5% probability that the result is “due to chance,” nor does it tell you the probability that the treatment works.

Effect size describes the magnitude of the observed difference between groups. It answers a different question from statistical significance: how large is the estimated difference? A p-value does not provide that magnitude. A small p-value can occur with either a large or a very small effect, depending on the data, sample size, variability, and statistical model. Effect size and its uncertainty therefore need to be examined separately from the p-value.

Clinical significance asks whether the observed change is large enough to matter to a patient in practice. Researchers sometimes use the concept of a minimal clinically important difference: the smallest change in an outcome measure that patients would typically perceive as meaningful. A change that falls below that threshold may be statistically real and yet practically irrelevant to anyone’s experience of their condition.

Two illustrative contrasts make this concrete:

In the first scenario, a PEMF study enrolls several hundred participants with chronic back discomfort. Because the sample is large, the study has strong statistical power. At the end of the trial, the active group shows a 0.3-point improvement on a 10-point pain scale compared to the sham group. This difference reaches p less than 0.05. The result is statistically significant. Suppose, purely for illustration, that the validated meaningful-change threshold for the outcome and population being studied were substantially larger than 0.3 points. The study observed a statistically significant but small between-group difference; statistical significance alone does not establish that the difference is clinically important.

In the second scenario, a small PEMF study enrolls 18 participants. The active group shows an average 2.5-point greater improvement than the comparison group on the same scale. Suppose, purely for illustration, that a difference of that magnitude would exceed an appropriate meaningful-change threshold for the population and outcome being studied. With only 9 participants per group, however, the estimate is imprecise and does not reach the study's threshold for statistical significance. The observed difference may be clinically interesting and hypothesis-generating, but the study does not establish whether that difference reflects a reproducible treatment effect.

When reading a PEMF abstract, the practical habit is to look for effect size alongside the p-value and ask: was this change large enough to matter? If the study does not report an effect size or a meaningful-change threshold, that itself is a limitation.

Common Assumption	Methodological Reality
A statistically significant result means the treatment is highly effective.	Statistical significance indicates that the observed data meet the study's predefined statistical criterion under the specified model. It does not tell you how large, important, or clinically meaningful the effect is.
An RCT guarantees the findings are reliable.	RCT design reduces selection bias when executed correctly. Poor allocation concealment, inadequate blinding, or small sample size can weaken that protection substantially.
If a study was published in a peer-reviewed journal, it must be good research.	Peer review filters for basic acceptability, not for methodological excellence. Published studies vary widely in design quality, reporting completeness, and sample size.
A null result proves the treatment does not work.	A null result in an underpowered study may simply mean the study lacked the statistical power to detect an effect that exists.
A large p-value means a small effect.	P-values and effect sizes are distinct. A large p-value can occur with either a small effect or an imprecisely estimated larger effect. Likewise, a small p-value in a sufficiently large study can accompany a very small effect.

 

Primary Endpoints, Selective Reporting, and Why Outcome Type Matters

A PEMF study may measure dozens of outcomes: pain scores, range of motion, biomarker levels, quality-of-life questionnaires, functional assessments, and more. When a study tests that many outcomes and then reports the ones that happened to reach statistical significance, the published positive finding may not represent a genuine treatment effect. It may represent chance. If you run enough comparisons, some will cross the significance threshold through random variation alone.

Two related problems can arise when a study measures many outcomes or performs many analyses. First, multiple testing creates more opportunities for chance findings unless the analysis appropriately accounts for multiplicity. Second, selective reporting occurs when researchers choose which outcomes, time points, or analyses to emphasize or publish after seeing the results. These problems can interact, but they are not the same methodological issue.

One important safeguard against outcome switching and selective reporting is prospective registration and prespecification. Researchers can identify the primary and secondary outcomes, important time points, and planned analyses before trial results are known, ideally before participant enrollment begins. Readers can then compare the published report with the trial registry, protocol, or statistical analysis plan to identify unexplained changes. Prespecification does not eliminate selective reporting by itself, but it makes such changes easier to detect.

A primary endpoint is a prespecified outcome designated as central to answering the study's main research question. Some trials have one primary endpoint, while others use multiple or co-primary endpoints. Secondary endpoints address additional prespecified questions, and their interpretation depends on the trial's analysis plan, including how multiple statistical tests were handled. Analyses or outcomes identified after seeing the data are generally considered exploratory or post hoc. Exploratory findings can generate useful hypotheses, but they should be distinguished clearly from prespecified confirmatory analyses.

Systematic reviews of particular PEMF evidence bases have identified methodological and reporting limitations, but those findings should remain tied to the studies the review actually examined rather than being generalized automatically to the entire PEMF literature. For example, a recent systematic review of randomized PEMF trials in knee osteoarthritis found substantial variation in intervention parameters and identified risk-of-bias concerns in several included trials; for three trials, selective-reporting risk could not be determined clearly because preregistered protocols were not identified. Findings like these are reasons to inspect reporting quality study by study, not evidence that every area of PEMF research has the same methodological problems.

Some objectively measured outcomes may be less directly influenced by participant expectations than self-reported outcomes, but “objective” does not mean bias-free. Imaging findings, biomarkers, and physiological measurements still depend on valid measurement methods, appropriate analysis, assessor procedures, and whether the endpoint itself is relevant to the clinical question. Subjective outcomes such as pain, symptoms, or quality of life can also be highly important because they measure experiences that matter directly to patients. Their credibility depends especially on outcome validity, blinding where feasible, missing-data handling, and the way the result was analyzed and reported.

When reading a PEMF result, two questions are worth asking: Was this the prespecified primary endpoint? Was it an objective or subjective measure? Both affect how much confidence the finding can support.

The PEMF-Specific Problem: What Happens When a Study Doesn’t Report Its Parameters

PEMF research faces a reporting challenge that distinguishes it from many other clinical interventions. When a study tests, say, a medication, the active compound can be precisely identified by its chemical structure and dose. When a study tests PEMF, “PEMF” by itself describes almost nothing. Two studies that both claim to test pulsed electromagnetic field therapy may have used entirely different field characteristics, and if those characteristics are not reported, there is no way to know whether the studies tested the same thing.

A useful PEMF study should report enough technical information to identify and reproduce the exposure. Important characteristics can include:

●       Frequency: how many cycles per second the electromagnetic field oscillates, typically expressed in hertz (Hz).

●       Field intensity: how strong the field is, typically expressed in gauss, tesla, or microtesla depending on the magnitude.

●       Waveform shape: the pattern of the pulsing, such as sinusoidal, square wave, or sawtooth.

●       Exposure duration: how long each session lasted and how frequently sessions occurred over the course of the study.

●       Device and applicator configuration: the device or applicator used, including relevant coil or applicator geometry, helps determine how the field is delivered spatially.

●       Applicator placement and measurement context: body area, orientation, distance from the applicator, and the location at which field intensity was measured can materially affect what the reported field-strength value means.

●       Pulse timing characteristics where applicable: pulse width, duty cycle, burst structure, rise/fall characteristics, or related timing information may be necessary to characterize pulsed signals that cannot be defined adequately by nominal frequency and peak intensity alone.

No single short checklist guarantees complete reproducibility because the technical information required depends on the device and signal architecture. However, when core characteristics such as frequency, field intensity and its measurement context, waveform or pulse structure, applicator configuration, placement, and exposure schedule are missing, researchers may be unable to reconstruct the intervention adequately or determine whether two studies tested meaningfully comparable exposures.

Incomplete or inconsistent technical reporting has been documented in parts of the PEMF literature. Recent systematic-review work in musculoskeletal applications has highlighted substantial heterogeneity in electromagnetic dosimetry and gaps in standardized reporting of parameters such as waveform and field-change characteristics. These limitations make cross-study comparison more difficult because interventions grouped under the same PEMF label may not represent equivalent exposures. The extent of the problem varies by evidence base, so parameter-reporting limitations should be assessed within the specific body of research being reviewed.

This article addresses why these parameters must be reported, not how specific parameter values affect physiological outcomes. That question belongs to a separate body of biophysical analysis.

When evaluating any PEMF study, use the following checklist to assess parameter reporting transparency:

Quality Marker	Why It Matters
Device / applicator described	Identifies the physical system producing the field and helps determine whether another study used a comparable applicator geometry.
Frequency or pulse repetition rate reported	Describes an important timing characteristic of the exposure, but must be interpreted with the other field parameters.
Field intensity reported with measurement context	A field-strength value is difficult to interpret without knowing where and how it was measured, because the field can change with distance, geometry, and position.
Waveform / pulse shape described	Interventions sharing nominal frequency and peak intensity can still differ substantially in how the field changes over time.
Pulse timing reported where applicable	Pulse width, duty cycle, burst structure, or related characteristics may be needed to characterize the signal adequately.
Applicator placement / body area described	Placement and orientation help define which region was exposed and how the exposure was delivered.

 

Why Replication Strengthens Confidence Beyond a Single Study

A single well-designed study can provide meaningful evidence, but confidence generally increases when findings are reproduced by independent research teams. Close replication asks whether a result can be reproduced under similar conditions, while broader or conceptual replication examines whether related findings persist across different populations, settings, or appropriately varied protocols. Consistency across rigorous studies therefore provides stronger evidence than reliance on one positive result alone.

Systematic reviews and meta-analyses can strengthen evidence assessment by identifying studies systematically, evaluating their limitations, and synthesizing findings across a body of research. For questions about intervention effects, a well-conducted systematic review of sufficiently comparable, high-quality trials can provide a stronger basis for inference than relying on any one study. Its conclusions, however, remain constrained by the quality, comparability, and completeness of the underlying evidence.

In practice, systematic reviews are constrained by the quality and comparability of what they aggregate. A review of ten small, poorly controlled studies with missing parameters does not produce evidence equivalent to ten large, well-controlled studies with complete reporting. Weak inputs produce a weak output, regardless of how rigorous the synthesis methodology is.

For PEMF research specifically, this constraint is particularly relevant. Systematic reviews of PEMF literature have consistently identified substantial heterogeneity across studies: differences in protocols, parameter values, population characteristics, outcome measures, and follow-up durations. When studies vary this much, pooling their results into a single estimate is difficult to interpret. Findings that appear in one context may not appear in another, and a pooled effect size may obscure as much as it reveals. Readers of PEMF meta-analyses should look carefully at how much heterogeneity existed across the included studies and whether reviewers explicitly discuss what that heterogeneity means for the reliability of their conclusions.

Consumer-facing claims such as “clinically proven” deserve scrutiny when they rely primarily on small pilot or feasibility studies. A pilot study is generally designed to test whether the methods and procedures planned for a larger study are feasible—for example recruitment, retention, randomization, intervention delivery, or outcome collection. It is not normally designed or powered to establish whether an intervention is effective. Because estimates of treatment effect from small pilot studies are highly imprecise, they should not be treated as confirmatory evidence of efficacy or used uncritically as the basis for strong product claims. Exploratory clinical outcomes can generate hypotheses, but efficacy should be evaluated in appropriately designed and adequately powered studies.

What This Evaluation Framework Does and Does Not Establish

The framework built across this article is a tool for understanding what a clinical study can reasonably support within its own context: the specific population enrolled, the specific device and protocol used, the specific outcomes measured, and the specific conditions of the study. A methodologically strong study with complete parameter reporting, credible blinding, adequate sample size, and a prespecified primary endpoint tells you something reliable about the intervention as it was applied in that study. That is genuinely valuable information.

What it does not tell you is what a different device, used by a different population, under different conditions, will produce. Even a methodologically strong study provides its most direct evidence about the intervention and conditions it actually tested. Applying those findings to a consumer device with different specifications requires a separate analytical step, one that examines whether the device in question operates under conditions comparable to those studied. That analysis falls outside the scope of this article. For the separate question of study-to-product applicability, see Do Clinical PEMF Studies Apply to Consumer PEMF Mats?

This boundary matters practically. Research evidence and product evidence are not interchangeable. A well-designed clinical study on one PEMF device does not, by itself, establish that a different device produces the same outcome. Recognizing where study evidence ends and product-specific evidence begins is part of responsible claim interpretation.

At HealthyLine, presenting this boundary clearly rather than obscuring it reflects a commitment to helping readers engage with PEMF research honestly. The goal of this content is to build the methodological literacy that allows someone to read a research claim, identify what it actually supports, and ask the right follow-up questions, not to create the impression that any study automatically validates any product. That kind of transparency is more useful than marketing language that treats every published study as proof of whatever is being sold.

FAQ

What is a double-blind PEMF study?

A double-blind PEMF study generally aims to keep both participants and outcome assessors unaware of whether active or sham exposure was assigned. A credible sham should reproduce the relevant participant experience of the active device as closely as possible without delivering the PEMF exposure being tested. Blinding may be easier when active exposure produces no perceptible heat, vibration, muscle contraction, sound, or other cue, but its credibility must be assessed in each individual study.

Readers should therefore look beyond the label “double-blind.” Did the active and sham devices create distinguishable sensations or cues? Were outcome assessors kept unaware of allocation? Did the researchers test whether participants could correctly guess their group assignment? A stated blinding method is useful, but evidence that the blinding was actually maintained is stronger.

Does a pilot study prove that PEMF works?

No. A pilot or feasibility study is primarily designed to determine whether the methods planned for a larger study can be carried out successfully—for example whether participants can be recruited and retained, whether the intervention can be delivered as planned, and whether study procedures are workable.

Pilot studies are generally too small to provide reliable tests of treatment efficacy, and treatment-effect estimates from them can be highly imprecise. Exploratory outcome findings may help generate questions for a later definitive trial, but they should not be treated as confirmation that PEMF works for the outcome being studied. The appropriate follow-up is a properly designed, adequately powered study focused on efficacy or effectiveness.

Why do some PEMF studies report different results even when testing the same condition?

One important reason is that studies may not have tested equivalent PEMF interventions even when both used the label “PEMF.” Studies frequently differ in the frequency, intensity, waveform, and exposure duration of the fields they applied. Because these characteristics are often incompletely reported, it can be difficult even for researchers to determine how much the protocols differed. Differences in parameter combinations and delivered exposure can contribute to different findings even when studies investigate the same condition.

Beyond protocol variability, studies also differ in design quality, sample size, population characteristics, outcome measures, and follow-up duration, all of which contribute to different results. This variability is one reason systematic reviews of PEMF research often report high heterogeneity among included studies, which limits how reliably their pooled conclusions can be interpreted. When results appear to conflict, the useful question is whether the studies used comparable protocols with comparable populations, rather than assuming the results are contradictory in a way that must mean one side is wrong.